657—20.2(124,126,155A) Definitions. For purposes of this chapter, the following definitions apply:
“Anticipatory compounding” means the compounding of preparations in advance of the pharmacy’s receipt of patient-specific prescriptions.
“Batch preparation compounding” means anticipatory compounding, compounding preparations intended for multiple disbursements, or compounding preparations in a multiple-dose container for administration to more than one patient.
“Beyond-use date” means the date after which a compounded preparation should not be used, determined from the date that the preparation is compounded.
“Bulk drug substance” means any substance that is represented for use in a drug and that, when used in the manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug. The term does not include intermediates used in the synthesis of such substances.
“Compounding” means the combining, mixing, diluting, pooling, flavoring, or otherwise altering of a drug or bulk drug substance to create a drug. Compounding includes the preparation of drugs or devices in which all bulk drug substances and components are nonprescription products. Compounding does not include the use of a flavoring agent to flavor a drug pursuant to rule 657—20.13(124,126,155A), nor does it include mixing or reconstituting a drug according to the product’s manufacturer label.
“FDA” means the Food and Drug Administration of the U.S. Department of Health and Human Services.
“Flavoring agent” means a therapeutically inert, nonallergenic substance consisting of inactive ingredients that is added to a drug to improve the drug’s taste and palatability.
“NABP information sharing network” means the information sharing network developed by the National Association of Boards of Pharmacy that collects, assesses, and allows review and sharing of pharmacy compounding information as described in the Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products between the board and the United States Food and Drug Administration.
“Office use” means that a compounded product has been prepared and distributed to a practitioner for administration to a patient by the practitioner in the course of the practitioner’s professional practice. A compounded product distributed to a practitioner for “office use” shall not require a patient-specific prescription and may not be further distributed to another practitioner or dispensed to a patient for self-administration.
“Outsourcing facility” or “facility” means any compounding facility that is registered as an outsourcing facility, as defined in 21 U.S.C. Section 353b, that distributes sterile compounded human drug products without a patient-specific prescription to an authorized agent or practitioner in this state.
“USP” means United States Pharmacopeia.
[ARC 2194C, IAB 10/14/15, effective 11/18/15; ARC 2559C, IAB 6/8/16, effective 7/13/16; ARC 3238C, IAB 8/2/17, effective 9/6/17; ARC 6076C, IAB 12/15/21, effective 1/19/22]